<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30235921</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2005-9256</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>19</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer research and treatment : official journal of Korean Cancer Association</Title>                <ISOAbbreviation>Cancer Res Treat</ISOAbbreviation>            </Journal>            <ArticleTitle>A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-dense Doxorubicin/cyclophosphamide.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.4143/crt.2018.383</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">Dose-dense chemotherapy (DD-CT) is a preferred (neo) adjuvant regimen in early breast cancer (BC). Although the results of reported randomized trials are conflicting, a recent meta-analysis showed improved overall and disease-free survival with DD-CT compared to conventional schedules. However, no DD-CT safety data for Korean BC patients are available. This phase II study was conducted to evaluate the safety and efficacy of pegteograstim in Korean BC patients receiving DD-CT.</AbstractText>                <AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">Patients with operable (stage I-III), histologically confirmed BC received four cycles of intravenous doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) on day 1 every two weeks as neoadjuvant or adjuvant therapy. Pegteograstim (6.0 mg) was administered subcutaneously on day 2 of each cycle. The primary endpoint was the incidence of febrile neutropenia (FN). The secondary endpoints were safety and tolerability.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Of 63 patients, one (1.6%) developed FN during all cycles of DD-CT. Dose delay was observed in four patients (6.3%) and dose reduction in two (3.2%) during DD-CT. Frequent adverse events (AEs) were nausea, alopecia, generalized muscle weakness, myalgia, mucositis, anorexia, dyspepsia, and diarrhea; most AEs were related to chemotherapy. Grade 3-4 AEs were reported in five of 63 patients (7.9%), and all grade 3 and 4 AEs were related to chemotherapy. Adverse drug reactions possibly linked to pegteograstim were abdominal pain, bone pain, myalgia, generalized muscle weakness, and headache in five of 63 patients (7.9%).</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Dose-dense AC chemotherapy with pegteograstim support is a tolerable and safe regimen in Korean early BC patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Gun Min</ForeName>                    <Initials>GM</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Joo Hoon</ForeName>                    <Initials>JH</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jeong</LastName>                    <ForeName>Ji Heung</ForeName>                    <Initials>JH</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cho</LastName>                    <ForeName>Young Up</ForeName>                    <Initials>YU</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Seung Il</ForeName>                    <Initials>SI</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Seho</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Hyung Seok</ForeName>                    <Initials>HS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Ji Ye</ForeName>                    <Initials>JY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sohn</LastName>                    <ForeName>Joohyuk</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>19</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>Cancer Res Treat</MedlineTA>            <NlmUniqueID>101155137</NlmUniqueID>            <ISSNLinking>1598-2998</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">Dose-dense chemotherapy</Keyword>            <Keyword MajorTopicYN="N">Pegfilgrastim</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30235921</ArticleId>            <ArticleId IdType="pii">crt.2018.383</ArticleId>            <ArticleId IdType="doi">10.4143/crt.2018.383</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>